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cable. This effect was taken into account during treatment 
planning. Position verification using the PermaDoc phantom 
confirmed this 1 mm retraction. All radiographically 
measured dead spaces complied with the specifications, 
except for the plastic needles which were 1 mm shorter than 
indicated. The center of the active source is at 2.42 mm from 
the tip of the capsule. Combined with the 1 mm source 
retraction, the center of the dose distribution at the most 
distal position located always 3.5 mm behind the internal 
end-point of the source channel. Radiographic and dosimetric 
dead space measurements showed good agreement (<0.5mm) 
for all applicators.  
 
 
 
Conclusion: Measured source position and dwell time 
accuracy comply with the vendor’s specifications. Small 
deviations were found for the dwell time accuracy at the 
most proximal source position. Similar tests should be 
performed regularly to warrant the mechanical accuracy of 
the afterloader and the quality of the applicators and 
transfer tubes.  
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Purpose or Objective: Dose verification and quality 
assurance in radiotherapy (RT) should be assessed in order to 
provide the best treatment possible and minimize risks for 
patient. In certain treatments there are no tools capable of 
performing real-time dose measurement. In addition, in-situ 
real-time dosimetry would enhance brachytherapy (BT) by 
providing technical conditions to perform treatment 
readjustment and real-time dose correction. Considering the 
current challenges, we developed a dosimeter intended for 
in-situ and real-time dosimetry in High Dose Rate 
brachytherapy (HDR-BT), e.g., prostate and breast. 
 
Material and Methods: The dosimeter developed has a 
sensitive 3 m long optical fiber probe of 1mm or 0.5 mm 
diameter comprehending a 5 mm length scintillating optical 
fiber. To read the signal produced at the probe, 1x1 mm2 
Silicon Photomultipliers (SiPM) from Hamamatsu were used. A 
custom made readout system with SiPM temperature 
compensation was used. The main concerns when performing 
dosimetry at high dose rates with high energy isotopes is the 
eventuality of Cherenkov light production. This form of noise 
accounts to the total noise signal, known as stem effect. 
The dosimeter was placed in a PMMA phantom and the 
response was evaluated with a 10.07 Ci Ir-192 HDR-
brachytherapy source (Nucletron). Measurements were 
repeated twice, first using a dummy probe without 
scintillator for stem effect quantification and second using an 
ionization chamber (IC) read by an electrometer for 
reference. 
Results: The studies carried out allowed assessing the 
amount of stem effect produced in the optical fiber cable. In 
the conditions described above, the stem effect contribution 
is lower than 1% for both 0.5 and 1 mm probes. The 
measurements of the fiber dosimeter response as a function 
of the dose are represented in Figure 1. The small difference 
from the reference IC is due to the different detector 
volumes of the fiber dosimeter and the ionization chamber. 
The dosimeter shows a linear response with dose rate being 
capable of detecting µGy dose variations. 
 
 
 
Figure 1: Fiber optic dosimeter stem-effect and response for 
0.5 and 1 mm diameter versions compared to ionization 
chamber response. 
 
Conclusion: The first round of in-vitro tests in clinical setting 
demonstrated that the fiber optical based dosimeters 
developed are suitable for dosimetry in regimes such as HDR 
prostate BT. The versatility of this kind of device and 
easiness of use allows application in other radiotherapy 
modalities. Besides fulfilling all the requirements for a 
dosimeter in HDR-BT, the high sensitivity of this device 
makes it a suitable candidate for application in LDR-BT.  
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Purpose or Objective: An intraoperatively built custom-
linked (IBCL) seeds system is a push-button seed delivery 
system that allows the user to create intraoperatively 
customized linked seeds, using a combination of seeds, 
connectors, and spacers. To date, only three studies have 
compared the implant quality of IBCL seeds to loose seeds for 
use in permanent prostate brachytherapy (PPB). However, 
they did not use sector analysis. Therefore, we compared the 
implant quality of IBCL seeds to loose seeds in PPB using 
sector analysis. 
 
Material and Methods: Between June 2012 and January 2015, 
64 consecutive prostate cancer patients underwent 
brachytherapy with IBCL seeds (n = 32) or loose seeds (n = 
32). All the patients were treated with 144Gy of 
brachytherapy alone. IBCL and loose seeds were alternately 
used basically. All patients were treated by the same 
radiation oncologist and urologist. We used the same dose–
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volume targets in the IBCL seed group and the loose seed 
group. Brachytherapy was performed using a dynamic dose 
calculation technique. Computed tomography/magnetic 
resonance imaging fusion-based dosimetry was performed 1 
month after brachytherapy. Post-implant dose volume 
histogram (DVH) parameters, prostate sector dosimetry, 
operation time, seed migration, and toxicities were 
compared between the two groups. A sector analysis tool was 
used to divide the prostate into six sectors (anterior and 
posterior sectors at the base, mid-gland, and apex). Analyses 
were performed using the 2-sample t test for continuous data 
that followed a normal distribution, the Mann-Whitney test 
for continuous data that did not follow a normal distribution, 
and the Chi-squared test for categorical data. Probability (P) 
values of < 0.05 were considered significant. 
 
Results: In prostate sector dosimetry, V100 (95.3% vs. 89.7%; 
P = 0.014) and D90 (169.7 Gy vs. 152.6 Gy; P = 0.013) in the 
anterior base sector were significantly higher in the IBCL 
seed group than in the loose seed group. Other post-implant 
DVH parameters did not differ significantly between the two 
groups. The seed migration rate was significantly lower in the 
IBCL seed group than in the loose seed group (6% vs. 66%; P < 
0.001). There was no significant difference in mean operation 
time between the two groups; however, mean operation time 
per seed was significantly longer in the IBCL seed group than 
in the loose seed group (1.31 min vs. 1.13 min; P = 0.003). 
The median follow-up was 18 months (range, 1-36 months). 
No significant differences in toxicities were seen between the 
two groups. 
 
Conclusion: Our study showed more dose coverage post-
operatively in the anterior base prostate sector and less seed 
migration in IBCL seeds implantation compared to loose seeds 
implantation. 
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Purpose or Objective: to evaluate results of saturation 
biopsy in candidates for focal, hemigland high dose rate 
(HDR) brachytherapy or irradiation with “low-dose tunnel for 
urethra” 
 
Material and Methods: Template guided saturation biopsy 
was performed in 52 primary patients with suspicion to 
prostate cancer and PSA below 10 ng/ml. Biopsy was 
performed under US control with the help of brachytherapy 
grid and 5mm distance between samples. During positioning 
and biopsy procedure we put special attention for accurate 
sampling of prostate in periurethral region. The number of 
cores varied from 17 to 50 (average 33 cores). Finally in 31 
patients with confirmed prostate cancer results of biopsy 
were used for brachytherapy planning. 
 
Results: Saturation biopsy revealed prostate cancer in 31 of 
52 evaluated patients. Involved volume ranged from 5% to 
100% (average - 57%). Focal nature of PC diagnosed in 6 
(19.4%), multifocal – in another 25 (80.6%) patients. 
Hemigland invasion mentioned in 10 cases. Saturation biopsy 
detected PC in periurethral cores in 22 (70.9%) of 31 
evaluated patients: invasion of one core revealed in 1, 2 
cores – in 6, 3 and more cores – in another 14 cases. In 10 
patients extent of involvement in periurethral cores varied 
between 10% and 50%, in another 12 observations exceeded 
50%. According to results obtained on saturation biopsy we 
performed HDR brachytherapy with “urethra low dose 
tunnel” (D10ur≤80%) in 9 patients with noninvolved 
periurethral cores. Theoretically hemigland brachytherapy 
was possible in 10 of 31 evaluated patients. 
 
Conclusion: in low risk patients with prostate cancer results 
of template guided saturation biopsy can significantly 
influence strategy of HDR brachytherapy 
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Purpose or Objective: We presented a retrospective analysis 
in 11 patients with histological proven local-recurrent 
prostate cancer, undergoing salvage BT, treated between 
February 2009 and December 2014. 
 
Material and Methods: The previous radical treatments 
were: 3 Low dose rate BT (LDR-BT) (145 Gy), one combined 
treatment with external radiotherapy (EBRT) (45 Gy) and 
LDR-BT (100 Gy), and 7 EBRT (68-74 Gy). Four patients have 
been rescued with LDR-BT and seven with High-Dose-Rate-BT 
(HDR-BT). All patients have a complete study with abdominal 
CT scan, pelvic MRI, and bone scan to diagnose local disease 
exclusively. LDR-BT patients received 145 Gy with 125I. HDR 
patients, has been treated with 30 Gy in 3 fractions of 10 Gy 
separated ten days. Median time to Biochemical failure (BF) 
from the first treatment was 48 months (12-114). All patients 
received previous hormonotherapy. Median time to rescue 
was 69 months (33-156). Toxicities were evaluated according 
with CTCAE scale (version 4.0). 
 
Results: Median follow-up: 26,5 months (3-72 m). The overall 
survival time was 98 months (65-174). At the end of the 
follow up, March of 2015, all patients are alive, nine (82%) 
without evidence of disease, one patients had a 
retroperitoneal failure 7 months after the salvage-BT and 
other patient was diagnosed of a solitary bone metastases at 
12 months. Median PSA nadir post-salvage-BT was 0.1 ng/ml 
(0-0,29). There were not grade 3 GU or GI toxicities. 100 % of 
LDR-BT patients presented acute GU-toxicity grade 2. Fifty-
seven % of the HDR-BT patients had GU-toxicity grade 1 (0% 
grade 2). 
 
Conclusion: Prostate BT is an effective and well tolerated 
reirradiation treatment in local-recurrent prostate cancer 
patients, with, few long-term toxicities, mainly in those 
treated with HDR-BT. 
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Purpose or Objective: The different conventional treatments 
for prostate cancer are multiple and for low-risk tumors, 
focal brachytherapy can be a therapeutic alternative option 
to active surveillance. However, this focal treatment remains 
still under evaluation and within the frame of the focal 
brachytherapy project conducted in Toulouse, we will 
present in this study two parts of the project: first, the 
contribution of multi-modal rigid and non-rigid registrations 
for localization and delineation of the treated volume, then 
the dosimetry evaluation after registration. 
 
Material and Methods: First step of prostate brachytherapy 
at our Institute consists in a contour-based non-rigid 
registration between MRI and US perfomed with Koelis 
software where positive biopsy trajectory is retrieved and a 
fiducial non-radioactive marker is implanted to localize the 
tumor focus. As a result of this localization, dosimetry was 
performed using VariSeed software, dose prescription is 
